Decision-support software for the industrial-scale chromatographic purification of antibodies
- PMID: 17630695
- DOI: 10.1021/bp070062u
Decision-support software for the industrial-scale chromatographic purification of antibodies
Abstract
The high therapeutic and financial value offered by polyclonal antibodies and their fragments has prompted extensive commercialization for the treatment of a wide range of acute clinical indications. Large-scale manufacture typically includes antibody-specific chromatography steps that employ custom-made affinity matrices to separate product-specific IgG from the remainder of the contaminating antibody repertoire. The high cost of such matrices necessitates efficient process design in order to maximize their economic potential. Techniques that identify the most suitable operating conditions for achieving desired levels of manufacturing performance are therefore of significant utility. This paper describes the development of a computer model that incorporates the effects of capacity changes over consecutive chromatographic operational cycles in order to identify combinations of protein load and loading flowrate that satisfy preset constraints of product yield and throughput. The method is illustrated by application to the manufacture of DigiFab, an FDA-approved polyclonal antibody fragment purified from ovine serum, which is used to treat digoxin toxicity (Protherics U.K. Limited). The model was populated with data obtained from scale-down experimental studies of the commercial-scale affinity purification step, which correlated measured changes in matrix capacity with the total protein load and number of resin re-uses. To enable a tradeoff between yield and throughput, output values were integrated together into a single metric by multi-attribute decision-making techniques to identify the most suitable flowrate and feed concentration required for achieving target levels of DigiFab yield and throughput. Results indicated that reducing the flowrate by 70% (from the current level) and using a protein load at the midpoint of the range currently employed at production scale (approximately 200-500 g/L) would provide the most satisfactory tradeoff between yield and throughput.
Similar articles
-
Characterisation of an industrial affinity process used in the manufacturing of digoxin-specific polyclonal Fab fragments.J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 15;848(1):88-96. doi: 10.1016/j.jchromb.2006.03.065. Epub 2006 May 23. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 16720112
-
Global Sensitivity Analysis for the determination of parameter importance in bio-manufacturing processes.Biotechnol Appl Biochem. 2008 Oct;51(Pt 2):79-90. doi: 10.1042/BA20070228. Biotechnol Appl Biochem. 2008. PMID: 18205624
-
The integrated simulation and assessment of the impacts of process change in biotherapeutic antibody production.Biotechnol Prog. 2006 Nov-Dec;22(6):1612-20. doi: 10.1021/bp0602000. Biotechnol Prog. 2006. PMID: 17137309
-
Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Food Chem Toxicol. 2008. PMID: 18328408 Review.
-
Protein purification using chromatography: selection of type, modelling and optimization of operating conditions.J Mol Recognit. 2009 Mar-Apr;22(2):65-76. doi: 10.1002/jmr.898. J Mol Recognit. 2009. PMID: 18546092 Review.
Cited by
-
Closed-loop optimization of chromatography column sizing strategies in biopharmaceutical manufacture.J Chem Technol Biotechnol. 2014 Oct;89(10):1481-1490. doi: 10.1002/jctb.4267. Epub 2013 Dec 26. J Chem Technol Biotechnol. 2014. PMID: 25506115 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources